Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET
Clearside Biomedical (Nasdaq: CLSD) has opened registration for a virtual key opinion leader (KOL) event on July 24, 2024, from 8:00 - 9:15 am ET. The webinar will focus on suprachoroidal drug delivery and its applications in retinal treatments, particularly for neovascular age-related macular degeneration (wet AMD). The event will feature presentations by renowned retinal experts:
1. Dr. David M. Brown, Director of Research at Retina Consultants Houston
2. Dr. Glenn C. Yiu, Professor of Ophthalmology at UC Davis
3. Dr. Victor Chong, Chief Medical Officer of Clearside Biomedical
The webinar will highlight the broad applicability and real-world experience with suprachoroidal drug delivery, ongoing clinical programs, and potential future development opportunities for Clearside.
Clearside Biomedical (Nasdaq: CLSD) ha aperto le registrazioni per un evento virtuale con esperti chiave (KOL) che si terrà il 24 luglio 2024, dalle 8:00 alle 9:15 ET. Il webinar si concentrerà sulla somministrazione di farmaci suprachoroidali e le sue applicazioni nei trattamenti retinici, in particolare per la degenrazione maculare legata all'età neovascolare (wet AMD). L'evento presenterà relazioni di esperti retinici di fama:
1. Dr. David M. Brown, Direttore della Ricerca presso Retina Consultants Houston
2. Dr. Glenn C. Yiu, Professore di Oftalmologia presso UC Davis
3. Dr. Victor Chong, Chief Medical Officer di Clearside Biomedical
Il webinar metterà in evidenza la ampia applicabilità e l'esperienza nel mondo reale con la somministrazione di farmaci suprachoroidali, i programmi clinici in corso e le potenziali opportunità di sviluppo futuro per Clearside.
Clearside Biomedical (Nasdaq: CLSD) ha abierto el registro para un evento virtual con líderes de opinión (KOL) que se llevará a cabo el 24 de julio de 2024, de 8:00 a 9:15 am ET. El seminario web se centrará en la administración de medicamentos supracoroidales y sus aplicaciones en tratamientos de retina, particularmente para la degeneración macular neovascular relacionada con la edad (wet AMD). El evento contará con presentaciones de expertos retinianos de renombre:
1. Dr. David M. Brown, Director de Investigación en Retina Consultants Houston
2. Dr. Glenn C. Yiu, Profesor de Oftalmología en UC Davis
3. Dr. Victor Chong, Director Médico de Clearside Biomedical
El seminario web destacará la amplia aplicabilidad y experiencia en el mundo real con la administración de medicamentos supracoroidales, los programas clínicos en curso y las posibles oportunidades de desarrollo futuro para Clearside.
Clearside Biomedical (Nasdaq: CLSD)는 2024년 7월 24일 오전 8시부터 9시 15분 ET까지 열리는 주요 의견 전문가(KOL) 가상 이벤트 등록을 시작했습니다. 이번 웨비나는 망막 치료를 위한 초코로이드 약물 전달 및 그 응용에 초점을 맞출 예정이며, 특히 신생혈관성 노인성 황반변성(wet AMD)에 대해 다룰 것입니다. 이 이벤트에는 저명한 망막 전문가들의 발표가 포함됩니다:
1. 드. 데이비드 M. 브라운, 휴스턴 망막 컨설턴트 연구 책임자
2. 드. 글렌 C. 이우, UC 데이비스 안과 교수
3. 드. 빅터 청, Clearside Biomedical의 최고 의학 책임자
이번 웨비나는 초코로이드 약물 전달의 폭넓은 적용 가능성과 실제 경험, 진행 중인 임상 프로그램 및 Clearside의 미래 개발 기회에 대해 강조할 것입니다.
Clearside Biomedical (Nasdaq: CLSD) a ouvert les inscriptions pour un événement virtuel avec des leaders d'opinion clés (KOL) qui se tiendra le 24 juillet 2024, de 8h00 à 9h15 ET. Le webinaire se concentrera sur l'administration de médicaments suprachoroïdiens et ses applications dans les traitements rétiniens, en particulier pour la dégénérescence maculaire néovasculaire liée à l'âge (wet AMD). L'événement présentera des interventions d'experts rétiniens de renom :
1. Dr. David M. Brown, Directeur de la recherche chez Retina Consultants Houston
2. Dr. Glenn C. Yiu, Professeur d'ophtalmologie à l'UC Davis
3. Dr. Victor Chong, Directeur médical de Clearside Biomedical
Le webinaire mettra en lumière la large applicabilité et l'expérience concrète concernant l'administration de médicaments suprachoroïdiens, les programmes cliniques en cours et les potentielles opportunités de développement futur pour Clearside.
Clearside Biomedical (Nasdaq: CLSD) hat die Registrierung für eine virtuelle Veranstaltung mit Schlüsselmeinungsführern (KOL) am 24. Juli 2024 von 8:00 bis 9:15 Uhr ET geöffnet. Das Webinar wird sich auf die suprachoroidale Medikamentenabgabe und deren Anwendungen in der Netzhautbehandlung konzentrieren, insbesondere bei der neovaskulären altersbedingten Makuladegeneration (nassen AMD). Die Veranstaltung wird Präsentationen von renommierten Netzhautexperten beinhalten:
1. Dr. David M. Brown, Forschungsdirektor bei Retina Consultants Houston
2. Dr. Glenn C. Yiu, Professor für Augenheilkunde an der UC Davis
3. Dr. Victor Chong, Chief Medical Officer von Clearside Biomedical
Das Webinar wird die breite Anwendbarkeit und die Erfahrungen aus der Praxis mit der suprachoroidalen Medikamentenabgabe, aktuellen klinischen Programmen und potenziellen zukünftigen Entwicklungsmöglichkeiten für Clearside hervorheben.
- Hosting a KOL event to showcase the potential of suprachoroidal drug delivery
- Featuring presentations from renowned retinal experts
- Focusing on applications in wet AMD, a significant market opportunity
- Highlighting ongoing clinical programs and future development opportunities
- None.
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), has opened registration for its virtual key opinion leader (KOL) event on Wednesday, July 24, 2024 from 8:00 - 9:15 am ET. To register for the event, click here.
The event will highlight the broad applicability and real-world experience with suprachoroidal drug delivery, the SCS as a differentiator in the retinal treatment landscape with a focus on neovascular age-related macular degeneration (wet AMD), and ongoing SCS clinical programs, including potential future development opportunities for Clearside.
The event will include presentations by the following retinal experts concluding with a live question-and-answer session with the KOLs and Clearside senior management:
- David M. Brown, MD, Director of Research, Retina Consultants Houston
- Glenn C. Yiu, MD, PhD, Professor of Ophthalmology, University of California, Davis
- Victor Chong, MD, MBA, Chief Medical Officer, Clearside Biomedical
Registration for Clearside’s Suprachoroidal KOL event is open and available at this link. The live and archived webcast and related slides will be accessible on the Clearside website under the Investors section: Events and Presentations.
Biographies of Retinal Specialists
David M. Brown, MD, Director of Research at Retina Consultants Houston, is a medical and surgical retinal specialist and clinical trial specialist. He has pioneered research in the areas of age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. He is the director of the Greater Houston Retina Research Center, a clinical professor of Ophthalmology at Baylor College of Medicine, the Vice-Chair for research at the Blanton Eye Institute at Houston Methodist Hospital and serves as the consultant retinal specialist for NASA. Dr. Brown received his medical degree from Baylor College of Medicine and completed ophthalmology and retina training at the University of Iowa.
Glenn C. Yiu, MD, PhD, is a Professor of Ophthalmology at the University of California, Davis, where he works as a clinician-scientist and cares for patients as a board-certified vitreoretinal surgeon. He earned his dual MD-PhD degrees at Harvard Medical School, residency training at the Massachusetts Eye & Ear Infirmary, and vitreoretinal fellowship at Duke. He joined UC Davis in 2014, where he leads a translational research program studying age-related macular degeneration (AMD) and other retinal diseases, with focus on ocular imaging technologies, gene editing and delivery, and animal models of retinal disease. He reported the first use of CRISPR-based genome editing as a treatment strategy for wet AMD, developed the use of microneedles for suprachoroidal gene delivery, and pioneered important studies on AMD and other retinal disease models in nonhuman primates. He also serves as the Associate Director of Davis-Based Medical Student Research and Director of Tele-ophthalmology at UC Davis, where he has pioneered a teleretinal screening program to expand eye screening among diabetic patients in California.
Victor Chong, MD, MBA, Chief Medical Officer of Clearside Biomedical, is a board-certified retinal specialist. Previously, Dr. Chong served as VP, Global Head of Retina DAS at Johnson & Johnson Innovative Medicine, Global Head of Medicine, Retinal Health at Boehringer Ingelheim and Head of Department and Consultant Ophthalmic Surgeon of Oxford Eye Hospital, a part of the Oxford University Hospitals. Dr. Chong graduated from the University of Glasgow Medical School (MBChB) with the Neil Arnott Prize, finished his ophthalmic training at Moorfields Eye Hospital and completed a retinal fellowship at the Institute of Ophthalmology and Moorfields Eye Hospital, London. He earned an M.D. by research in Ophthalmology from King’s College, an MBA from Quantic School of Business and Technology and a MPhil in Cell Biology and Pathology from University College London.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com and follow us on LinkedIn and X.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include statements regarding the potential benefits of CLS-AX, Clearside’s suprachoroidal delivery technology and Clearside’s SCS Microinjector®, and potential future clinical development opportunities and pipeline expansion for Clearside. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control and other risks and uncertainties that are described in Clearside’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC) on March 12, 2024 and Clearside’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206
Source: Clearside Biomedical, Inc.
FAQ
When is Clearside Biomedical (CLSD) hosting its Suprachoroidal Delivery KOL Webinar?
Who are the key opinion leaders presenting at Clearside Biomedical's (CLSD) webinar?
What is the main focus of Clearside Biomedical's (CLSD) upcoming KOL webinar?
How can investors register for Clearside Biomedical's (CLSD) July 24, 2024 KOL webinar?
